Evaluation of glucocorticosteroid injection for the treatment of trochanteric bursitis.
OBJECTIVE
We conducted an open observational study to assess the short and longterm effect of single local glucocorticosteroid injection for trochanteric bursitis.


METHODS
75 patient diagnosed with trochanteric bursitis based on clinical criteria were injected; 20, 32, and 22 patients each received 6, 12, and 24 mg betamethasone, respectively, mixed with 4 cm3 of 1% lidocaine. A standardized baseline questionnaire was administered to assess the severity and functional limitation due to trochanteric pain, including the visual analog scale for pain. Patients were followed at Weeks 1, 6, and 26 to determine their response to treatment.


RESULTS
77.1, 68.8, 61.3% of responding patients reported improvement in pain at Week 1, 6, and 26, respectively. Patients receiving higher doses of betamethasone were more likely to experience pain relief (p < 0.0123).


CONCLUSIONS
Corticosteroid and lidocaine injection for trochanteric bursitis is an effective therapy with prolonged benefit.
Shbeeb
M I
MI
Division of Rheumatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
O'Duffy
J D
JD
Michet
C J
CJ
O'Fallon
W M
WM
Matteson
E L
EL
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001623:Betamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D002062:Bursitis / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005269:Femur; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000503:physiopathology; D010147:Pain Measurement; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D001623:Betamethasone